GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Net Change in Cash

IRIDEX (IRIDEX) Net Change in Cash

: $-6.89 Mil (TTM As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

IRIDEX's Net Change in Cash for the three months ended in Dec. 2023 was $-0.95 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.89 Mil.

IRIDEX Net Change in Cash Historical Data

The historical data trend for IRIDEX's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.54 -1.03 12.23 -9.93 -6.89

IRIDEX Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.93 -2.87 -1.23 -1.84 -0.95

IRIDEX Net Change in Cash Calculation

IRIDEX's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-6.745+-0.109+-0.005+-0.029
=-6.89

IRIDEX's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.979+0.032+0.045+-0.045
=-0.95

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IRIDEX Net Change in Cash Related Terms

Thank you for viewing the detailed overview of IRIDEX's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

IRIDEX (IRIDEX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Net Change in Cash
Comparable Companies
APYX CTSO RBOT DHAI LFWD ICAD ICCM NSPR AMIX RPID TSE:5212 ABT SYK MDT BSX EW DXCM SZSE:300760 ZBH ALGN
Traded in Other Exchanges
N/A
Address
1212 Terra Bella Avenue, Mountain View, CA, USA, 94043
Website
https://www.iridex.com
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Executives
Nandini Devi director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss director C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove director 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp 10 percent owner 75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp 10 percent owner 111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad officer: Interim CFO 461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous director C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda director 402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer officer: COO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne director
Robert A Gunst director
David Bruce director, officer: President and CEO 1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum director
Romeo R Dizon other: Vice President and Controller 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043

IRIDEX (IRIDEX) Headlines

From GuruFocus

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews • 06-01-2022

Iridex to Report Second Quarter Financial Results on August 10, 2023

By Marketwired • 07-27-2023

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews • 06-21-2022

Iridex to Participate in Fireside Chat with Stifel Equity Research

By Value_Insider Value_Insider • 12-06-2022

Iridex Reports Second Quarter 2023 Financial Results

By Marketwired • 08-10-2023

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021

By GuruFocusNews GuruFocusNews • 01-11-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews • 05-12-2022

Iridex Announces First Quarter 2022 Financial Results

By GuruFocusNews GuruFocusNews • 05-22-2022

Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

By sperokesalga sperokesalga • 02-23-2023

Iridex to Report Second Quarter 2022 Financial Results on August 15, 2022

By PurpleRose PurpleRose • 08-01-2022